These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
4. What happened to the coxibs on the way to the cardiologist? Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326 [No Abstract] [Full Text] [Related]
5. Learning the value of drugs--is rofecoxib a regulatory success story? Eisenberg RS N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222 [No Abstract] [Full Text] [Related]
6. Rofecoxib, Merck, and the FDA. Villalba L; Witter J N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745 [No Abstract] [Full Text] [Related]
7. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals. Lanzafame RJ Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023 [No Abstract] [Full Text] [Related]
8. What ails the FDA? Gorelick KJ N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814 [No Abstract] [Full Text] [Related]
9. What is a 'safe' drug? Healy B US News World Rep; 2004 Dec; 137(21):37. PubMed ID: 15636504 [No Abstract] [Full Text] [Related]
10. Lessons on prescribing and drug safety from the withdrawal of rofecoxib. Nelson M; Cicuttini F Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913 [No Abstract] [Full Text] [Related]
11. What ails the FDA? Okie S N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660 [No Abstract] [Full Text] [Related]
12. Raising the safety bar--the FDA's coxib meeting. Okie S N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221 [No Abstract] [Full Text] [Related]
13. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Fendrick AM Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263 [No Abstract] [Full Text] [Related]
14. Reflections on the withdrawal of rofecoxib. Dalby AJ Cardiovasc J S Afr; 2005; 16(1):5-6. PubMed ID: 15562323 [No Abstract] [Full Text] [Related]
15. Cyclooxygenase-2 inhibitors and cardiovascular risk. Smith ER Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124 [No Abstract] [Full Text] [Related]
16. The Vioxx debacle revisited. Daikh DI Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908 [No Abstract] [Full Text] [Related]
17. Europe also needs agency for postmarketing surveillance. Garattini S BMJ; 2005 Mar; 330(7490):540. PubMed ID: 15746147 [No Abstract] [Full Text] [Related]
18. The Vioxx debacle revisited. Good CB; Kelley CL Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902 [No Abstract] [Full Text] [Related]
19. Cardiovascular complications of COX2 selective inhibitors cause considerable concern. Hedner T; Himmelmann A Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147 [No Abstract] [Full Text] [Related]
20. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related] [Next] [New Search]